Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATOS
DateTimeSourceHeadlineSymbolCompany
12/03/202513:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
11/03/202512:15GlobeNewswire Inc.Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional IndicationsNASDAQ:ATOSAtossa Therapeutics Inc
24/02/202521:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
07/02/202521:09Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATOSAtossa Therapeutics Inc
05/02/202513:00GlobeNewswire Inc.Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer CareNASDAQ:ATOSAtossa Therapeutics Inc
04/02/202514:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
30/01/202513:17GlobeNewswire Inc.Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591NASDAQ:ATOSAtossa Therapeutics Inc
23/01/202513:15GlobeNewswire Inc.Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025NASDAQ:ATOSAtossa Therapeutics Inc
06/01/202514:00GlobeNewswire Inc.Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
12/12/202413:15GlobeNewswire Inc.Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumNASDAQ:ATOSAtossa Therapeutics Inc
11/12/202413:15GlobeNewswire Inc.Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast DensityNASDAQ:ATOSAtossa Therapeutics Inc
10/12/202414:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
10/12/202414:05GlobeNewswire Inc.Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer SymposiumNASDAQ:ATOSAtossa Therapeutics Inc
09/12/202413:15GlobeNewswire Inc.Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer ResearchNASDAQ:ATOSAtossa Therapeutics Inc
21/11/202413:30GlobeNewswire Inc.Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer ResearchNASDAQ:ATOSAtossa Therapeutics Inc
20/11/202413:30GlobeNewswire Inc.Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumNASDAQ:ATOSAtossa Therapeutics Inc
19/11/202421:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
19/11/202421:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATOSAtossa Therapeutics Inc
12/11/202413:30GlobeNewswire Inc.Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
08/11/202419:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATOSAtossa Therapeutics Inc
05/11/202413:30GlobeNewswire Inc.Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product DevelopmentNASDAQ:ATOSAtossa Therapeutics Inc
04/11/202411:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
04/11/202411:30GlobeNewswire Inc.Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:NASDAQ:ATOSAtossa Therapeutics Inc
31/10/202412:15GlobeNewswire Inc.Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
22/10/202419:24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ATOSAtossa Therapeutics Inc
21/10/202412:30GlobeNewswire Inc.Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
14/10/202421:08GlobeNewswire Inc.Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual SummitNASDAQ:ATOSAtossa Therapeutics Inc
01/10/202412:30GlobeNewswire Inc.Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment ContinuumNASDAQ:ATOSAtossa Therapeutics Inc
10/09/202412:30GlobeNewswire Inc.Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
03/09/202412:30GlobeNewswire Inc.Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATOS